Preclinical News and Research

RSS

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

RegeneRx Biopharmaceuticals, Inc. announced today that in a preclinical research paper published in the May 2010 issue of the Journal of Neurosurgery, (online ahead of publication), scientists found that the systemic administration of thymosin beta 4, or Tβ4, significantly reduced brain tissue damage and improved brain function in rats with traumatic brain injury, or TBI.

24 May 2010

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.

24 May 2010

Phase 1 clinical trial of OXY111A initiated

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications.

24 May 2010

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial with Lytixar (LTX-109) for nasal decolonisation of MRSA.

24 May 2010

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell $21.0 million of shares of its Series 5 Preferred Stock in a registered offering to three institutional investors (collectively, the "Initial Purchasers"). Each share of Series 5 Preferred Stock is convertible at the option of the holder, at any time during its existence, into 2,500 shares of common stock at a conversion price of $0.40 per share of common stock, for a total of 52,500,000 shares of common stock.

24 May 2010

IGF1 drug improves nerve cell communication in PMS mouse model

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS).

21 May 2010

Cancer Institute of New Jersey investigators target autophagy

In an effort to improve current anticancer treatments, investigators at The Cancer Institute of New Jersey (CINJ) have been targeting a process known as autophagy, in which cancer cells eat themselves as a measure of self preservation under chemotherapy and radiation stress, thus prolonging tumor cell survival and inducing resistance to therapy.

21 May 2010

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

Researchers from Mount Sinai School of Medicine have identified a drug that improves communication between nerve cells in a mouse model of Phelan-McDermid Syndrome (PMS). Behavioral symptoms of PMS fall under the autism spectrum disorder category. The research will be presented Friday at the International Meeting for Autism Research (IMFAR) in Philadelphia.

21 May 2010

New research seeks customised treatment of cardiovascular diseases

The Centre for Cooperative Research in Biomaterials, CIC biomaGUNE, is involved in the research consortium of cvREMOD, which aims to move forward in the attainment of new diagnosis techniques for prevention and customised treatment of cardiovascular diseases in the upcoming four years.

21 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.

21 May 2010

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Toxcure, LLC, an emerging specialty biopharmaceutical company, today announced the grant of U.S. Patent No. 7,709,440, which provides Toxcure with intellectual property protection for a method of treating various tumors with neurotoxins.

21 May 2010

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals, Inc. today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL.

21 May 2010

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

Angiogenesis plays a crucial role in neoplastic and non-neoplastic chronic inflammatory disorders, including inflammatory bowel diseases (IBD). Several reports have shown that blockade of angiogenesis in preclinical models of IBD is a promising new therapeutic approach. Visualize angiogenesis in vivo may represent the first step for such a therapeutic approach. Narrow-band imaging (NBI) is a new endoscopic technology that highlights mucosal surface structures and microcapillaries.

21 May 2010

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

Amsterdam Molecular Therapeutics a world leader in gene therapy, today reported positive preclinical data from a study using an AAV gene therapy product to lower cholesterol.

21 May 2010

TAP to unveil innovative RAFT system at TERMIS Conference

The Automation Partnership, a world leader in the design and development of innovative automation for life science applications, is pleased to announce it will be unveiling RAFT (Real Architecture for 3D Tissue), its innovative system for generating reproducible, 3D collagen tissue constructs on TAP Stand 1 at the Tissue Engineering and Regenerative Medicine International Society Conference on June 13-17, in Galway, Ireland.

20 May 2010

BioLife Solutions first-quarter revenue up 36% to $513,000

BioLife Solutions, Inc., announced today that Chairman and Chief Executive Officer Mike Rice issued the following letter to shareholders providing a general corporate update.

20 May 2010

NeuroTherapeutics Pharma closes $43 million Series B financing round

NeuroTherapeutics Pharma, Inc. (NTP), a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced today that it closed a $43 million Series B financing. New investors include Fidelity Biosciences, MPM Capital and SR One, who co-led the transaction, and Pfizer, Inc. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round.

20 May 2010

Study shows plexiform lesion develops in experimental rat model of severe PAH

A new preclinical model of pulmonary arterial hypertension may lead to improved research and ultimately better therapies for this life-threatening problem, according to its developers, researchers at the University of South Alabama.

20 May 2010

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

Inspire Pharmaceuticals, Inc. announced today that Inspire scientists and collaborators will present data on denufosol tetrasodium, an investigational therapy for cystic fibrosis, during an oral presentation at the American Thoracic Society 2010 International Conference May 14 - 19, 2010 in New Orleans, LA.

20 May 2010

Preclinical News and Research

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Phase 1 clinical trial of OXY111A initiated

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

IGF1 drug improves nerve cell communication in PMS mouse model

Cancer Institute of New Jersey investigators target autophagy

Researchers identify drug that improves communication between nerve cells in Phelan-McDermid Syndrome

New research seeks customised treatment of cardiovascular diseases

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Toxcure granted U.S. patent for method of treating neoplasms with neurotoxins

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

AMT reports positive preclinical data from cholesterol targeting AAV gene therapy study

TAP to unveil innovative RAFT system at TERMIS Conference

BioLife Solutions first-quarter revenue up 36% to $513,000

NeuroTherapeutics Pharma closes $43 million Series B financing round

Study shows plexiform lesion develops in experimental rat model of severe PAH

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics